Pharmacotherapeutic Options for Visceral Leishmaniasis—Current Scenario
Visceral leishmaniasis (VL) or Kala-azar is a protozoal disease, which was previously regarded as one of the most neglected tropical diseases. Management of this disease is quite difficult, because it is said to affect the poorest of the poor. Previously Sodium Stibogluconate (SSG) was regarded as t...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2009-01-01
|
| Series: | Clinical Medicine Insights: Pathology |
| Online Access: | https://doi.org/10.4137/CPath.S821 |
| _version_ | 1811193700577968128 |
|---|---|
| author | Krishna Pandey MD Prabhat Kumar Sinha Vidyanand Ravi Das Sanjiva Bimal Shubhankar K. Singh Pradeep Das |
| author_facet | Krishna Pandey MD Prabhat Kumar Sinha Vidyanand Ravi Das Sanjiva Bimal Shubhankar K. Singh Pradeep Das |
| author_sort | Krishna Pandey MD |
| collection | DOAJ |
| description | Visceral leishmaniasis (VL) or Kala-azar is a protozoal disease, which was previously regarded as one of the most neglected tropical diseases. Management of this disease is quite difficult, because it is said to affect the poorest of the poor. Previously Sodium Stibogluconate (SSG) was regarded as the gold standard treatment for VL. But due to the increasing unresponsiveness, to this drug various other drugs were tried and are still being tried. Pentamidine is very toxic and has been discarded of late. Amphotericin B and its lipid formulations are very effective but require hospital admission and monitoring. Oral drugs like Miltefosine have already been launched. An amino glycoside Paromomycin and another oral drug Sitamaquine are in the pipe line. Interferon gamma has been used with discouraging results. |
| first_indexed | 2024-04-12T00:14:03Z |
| format | Article |
| id | doaj.art-9505072642e542f5909ed575be822ac2 |
| institution | Directory Open Access Journal |
| issn | 1179-5557 |
| language | English |
| last_indexed | 2024-04-12T00:14:03Z |
| publishDate | 2009-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Clinical Medicine Insights: Pathology |
| spelling | doaj.art-9505072642e542f5909ed575be822ac22022-12-22T03:55:54ZengSAGE PublishingClinical Medicine Insights: Pathology1179-55572009-01-01210.4137/CPath.S821Pharmacotherapeutic Options for Visceral Leishmaniasis—Current ScenarioKrishna Pandey MD0Prabhat Kumar Sinha1Vidyanand Ravi Das2Sanjiva Bimal3Shubhankar K. Singh4Pradeep Das5Rajendra Memorial Research Institute of Medical Sciences (ICMR), Agamkuan, Patna-800 007, Bihar, India.Rajendra Memorial Research Institute of Medical Sciences (ICMR), Agamkuan, Patna-800 007, Bihar, India.Rajendra Memorial Research Institute of Medical Sciences (ICMR), Agamkuan, Patna-800 007, Bihar, India.Rajendra Memorial Research Institute of Medical Sciences (ICMR), Agamkuan, Patna-800 007, Bihar, India.Rajendra Memorial Research Institute of Medical Sciences (ICMR), Agamkuan, Patna-800 007, Bihar, India.Rajendra Memorial Research Institute of Medical Sciences (ICMR), Agamkuan, Patna-800 007, Bihar, India.Visceral leishmaniasis (VL) or Kala-azar is a protozoal disease, which was previously regarded as one of the most neglected tropical diseases. Management of this disease is quite difficult, because it is said to affect the poorest of the poor. Previously Sodium Stibogluconate (SSG) was regarded as the gold standard treatment for VL. But due to the increasing unresponsiveness, to this drug various other drugs were tried and are still being tried. Pentamidine is very toxic and has been discarded of late. Amphotericin B and its lipid formulations are very effective but require hospital admission and monitoring. Oral drugs like Miltefosine have already been launched. An amino glycoside Paromomycin and another oral drug Sitamaquine are in the pipe line. Interferon gamma has been used with discouraging results.https://doi.org/10.4137/CPath.S821 |
| spellingShingle | Krishna Pandey MD Prabhat Kumar Sinha Vidyanand Ravi Das Sanjiva Bimal Shubhankar K. Singh Pradeep Das Pharmacotherapeutic Options for Visceral Leishmaniasis—Current Scenario Clinical Medicine Insights: Pathology |
| title | Pharmacotherapeutic Options for Visceral Leishmaniasis—Current Scenario |
| title_full | Pharmacotherapeutic Options for Visceral Leishmaniasis—Current Scenario |
| title_fullStr | Pharmacotherapeutic Options for Visceral Leishmaniasis—Current Scenario |
| title_full_unstemmed | Pharmacotherapeutic Options for Visceral Leishmaniasis—Current Scenario |
| title_short | Pharmacotherapeutic Options for Visceral Leishmaniasis—Current Scenario |
| title_sort | pharmacotherapeutic options for visceral leishmaniasis current scenario |
| url | https://doi.org/10.4137/CPath.S821 |
| work_keys_str_mv | AT krishnapandeymd pharmacotherapeuticoptionsforvisceralleishmaniasiscurrentscenario AT prabhatkumarsinha pharmacotherapeuticoptionsforvisceralleishmaniasiscurrentscenario AT vidyanandravidas pharmacotherapeuticoptionsforvisceralleishmaniasiscurrentscenario AT sanjivabimal pharmacotherapeuticoptionsforvisceralleishmaniasiscurrentscenario AT shubhankarksingh pharmacotherapeuticoptionsforvisceralleishmaniasiscurrentscenario AT pradeepdas pharmacotherapeuticoptionsforvisceralleishmaniasiscurrentscenario |